Prenatal parvovirus B19 infection.
Anemia
Hydrops
Infection
Parvovirus B19
Prenatal
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
07
07
2024
accepted:
09
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Parvovirus B19 (B19V) causes erythema infectiosum, a.k.a., fifth disease. This disease primarily affects children. It is generally self-limiting and subsides after 1-2 weeks. In pregnancy, the virus can cross the placenta and result in a fetal infection. This may lead to severe fetal anemia, hydrops fetalis, a miscarriage, or intrauterine fetal death. The risk of long-term sequelae also appears to be increased. About one-third of pregnant women are not immune to B19V and, therefore, are at risk to contract a primary infection. The seroconversion rate during pregnancy is generally around 1-2%. During a primary infection, maternal-fetal transplacental transmission of B19V occurs in about 30-50% of the cases and the risk of fetal infection increases with advancing gestational age. The risk of severe fetal anemia or hydrops is around 3-4% overall and is around 6-7% if the primary infection occurs before 20 weeks' gestation. Fetal monitoring in women with a primary B19V infection includes regular ultrasound examinations looking for evidence of hydrops fetalis and Doppler measurements of the middle cerebral artery peak velocity. Fetal blood sampling is performed if a significant anemia is suspected and, if such is found, an intrauterine blood transfusion is needed. This article provides an overview of the epidemiology, pathogenesis, clinical manifestations, diagnostic methods, and management of B19V infection during pregnancy.
Identifiants
pubmed: 39073431
doi: 10.1007/s00404-024-07644-6
pii: 10.1007/s00404-024-07644-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Nordholm AC, Møller FT, Ravn SF et al (2024) Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, january to march 2024. Eurosurveillance 29:2400299. https://doi.org/10.2807/1560-7917.es.2024.29.24.2400299
doi: 10.2807/1560-7917.es.2024.29.24.2400299
pubmed: 38873795
pmcid: 11177569
Patalon T, Saciuk Y, Trotzky D et al (2023) An Outbreak of parvovirus B19 in Israel. Viruses 15:2261. https://doi.org/10.3390/v15112261
doi: 10.3390/v15112261
pubmed: 38005937
pmcid: 10674631
Russcher A, van Boven M, Benincà E et al (2024) Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic. Sci Rep 14:9630. https://doi.org/10.1038/s41598-024-59582-7
doi: 10.1038/s41598-024-59582-7
pubmed: 38671058
pmcid: 11053065
Beck R, Exler S, Enders M (2024) Parvovirus B19-Infektion und Schwangerschaft. Epid Bull 24:3–7. https://doi.org/10.25646/12157
S2k-Leitlinie - Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. AWMF Registernummer 093/001. https://register.awmf.org/de/leitlinien/detail/093-001 . Accessed 1 July 2024
Khalil A, Sotiriadis A, Chaoui R et al (2020) ISUOG Practice guidelines: role of ultrasound in congenital infection. Ultrasound Obstet Gynecol 56:128–151. https://doi.org/10.1002/uog.21991
doi: 10.1002/uog.21991
pubmed: 32400006
Qiu J, Söderlund-Venermo M, Young NS (2017) Human parvoviruses. Clin Microbiol Rev 30:43–113. https://doi.org/10.1128/cmr.00040-16
doi: 10.1128/cmr.00040-16
pubmed: 27806994
Crowcroft N, Roth C, Cohen B, Miller E (1999) Guidance for control of parvovirus B19 infection in healthcare settings and the community. J Public Heal 21:439–446. https://doi.org/10.1093/pubmed/21.4.439
doi: 10.1093/pubmed/21.4.439
Riipinen A, Sallmén M, Hedman L et al (2014) Increased risk of human parvovirus B19 infection in day-care employees: a cohort study among pregnant workers during an epidemic in Finland. Occup Environ Med 71:836. https://doi.org/10.1136/oemed-2014-102217
doi: 10.1136/oemed-2014-102217
pubmed: 25074899
Enders M, Weidner A, Enders G (2006) Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect 135:563–569. https://doi.org/10.1017/s095026880600731x
doi: 10.1017/s095026880600731x
pubmed: 17064457
pmcid: 2870617
Schwarz T, Roggendorf M, Hottenträger B et al (1988) Human parvovirus B19 Infection in pregnancy. Lancet 332:566–567. https://doi.org/10.1016/s0140-6736(88)92684-0
doi: 10.1016/s0140-6736(88)92684-0
Reinheimer C, Allwinn R, Doerr HW, Wittek M (2010) Seroepidemiology of parvovirus B19 in the frankfurt am main area, Germany: evaluation of risk factors. Infection 38:381–385. https://doi.org/10.1007/s15010-010-0035-y
doi: 10.1007/s15010-010-0035-y
pubmed: 20556472
Röhrer C, Gärtner B, Sauerbrei A et al (2007) Seroprevalence of parvovirus B19 in the German population. Epidemiology Infect 136:1564–1575. https://doi.org/10.1017/s0950268807009958
doi: 10.1017/s0950268807009958
Vyse AJ, Andrews NJ, Hesketh LM, Pebody R (2006) The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiology Infect 135:1354–1362. https://doi.org/10.1017/s0950268807007856
doi: 10.1017/s0950268807007856
Jensen IP, Thorsen P, Jeune B et al (2000) An epidemic of parvovirus B19 in a population of 3596 pregnant women: a study of sociodemographic and medical risk factors. BJOG Int J Obstet Gynaecol 107:637–643. https://doi.org/10.1111/j.1471-0528.2000.tb13306.x
doi: 10.1111/j.1471-0528.2000.tb13306.x
Oiwa H, Shimada T, Hashimoto M et al (2011) Clinical findings in parvovirus B19 infection in 30 adult patients in Kyoto. Mod Rheumatol 21:24–31. https://doi.org/10.1007/s10165-010-0338-y
doi: 10.1007/s10165-010-0338-y
pubmed: 20680378
Harger JH, Adler SP, Koch WC, Harger GF (1998) Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 91:413–420. https://doi.org/10.1016/s0029-7844(97)00701-1
doi: 10.1016/s0029-7844(97)00701-1
pubmed: 9491870
Florea AV, Ionescu DN, Melhem MF (2007) Parvovirus B19 Infection in the Immunocompromised Host. Arch Pathol Lab Med 131:799–804. https://doi.org/10.5858/2007-131-799-pbiiti
doi: 10.5858/2007-131-799-pbiiti
pubmed: 17488170
Attwood LO, Holmes NE, Hui L (2020) Identification and management of congenital parvovirus B19 infection. Prenat Diagn 40:1722–1731. https://doi.org/10.1002/pd.5819
doi: 10.1002/pd.5819
pubmed: 32860469
Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvovirus B19 infection. J Intern Med 260:285–304. https://doi.org/10.1111/j.1365-2796.2006.01697.x
doi: 10.1111/j.1365-2796.2006.01697.x
pubmed: 16961667
Bascietto F, Liberati M, Murgano D et al (2018) Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. Ultrasound Obst Gyn 52:569–576. https://doi.org/10.1002/uog.19092
doi: 10.1002/uog.19092
Koch WC, Harger JH, Barnstein B, Adler SP (1998) Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 17:489–494. https://doi.org/10.1097/00006454-199806000-00011
doi: 10.1097/00006454-199806000-00011
pubmed: 9655540
Miller E, Fairley CK, Cohen BJ, Seng C (1998) Immediate and long term outcome of human parvovirus B19 infection in pregnancy. BJOG Int J Obstet Gynaecol 105:174–178. https://doi.org/10.1111/j.1471-0528.1998.tb10048.x
doi: 10.1111/j.1471-0528.1998.tb10048.x
Morère L, Andouard D, Labrousse F et al (2015) Ex vivo model of congenital cytomegalovirus infection and new combination therapies. Placenta 36:41–47. https://doi.org/10.1016/j.placenta.2014.11.003
doi: 10.1016/j.placenta.2014.11.003
pubmed: 25479789
Enders M, Weidner A, Zoellner I et al (2004) Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 24:513–518. https://doi.org/10.1002/pd.940
doi: 10.1002/pd.940
pubmed: 15300741
Enders M, Klingel K, Weidner A et al (2010) Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection. J Clin Virol 49:163–168. https://doi.org/10.1016/j.jcv.2010.07.014
doi: 10.1016/j.jcv.2010.07.014
pubmed: 20729141
Xiong Y, Tan J, Liu Y et al (2019) The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis. J Clin Virol 114:12–20. https://doi.org/10.1016/j.jcv.2019.03.004
doi: 10.1016/j.jcv.2019.03.004
pubmed: 30897374
Hartge DR, Weichert J, Gembicki M, Krapp M (2015) Confirmation of etiology in fetal hydrops by sonographic evaluation of fluid allocation patterns. Eur J Obstet Gynecol Reprod Biol 195:128–132. https://doi.org/10.1016/j.ejogrb.2015.09.006
doi: 10.1016/j.ejogrb.2015.09.006
pubmed: 26540593
Grubman O, Hussain FN, Nelson Z, Brustman L (2019) Maternal parvovirus B19 Infection causing first-trimester increased nuchal translucency and fetal hydrops. Case Rep Obstet Gynecol 2019:3259760. https://doi.org/10.1155/2019/3259760
doi: 10.1155/2019/3259760
pubmed: 31360565
pmcid: 6642751
Smulian JC, Egan JFX, Rodis JF (1998) Fetal hydrops in the first trimester associated with maternal parvovirus infection. J Clin Ultrasound 26:314–316. https://doi.org/10.1002/(sici)1097-0096(199807/08)26:6%3c314::aid-jcu6%3e3.0.co;2-l
doi: 10.1002/(sici)1097-0096(199807/08)26:6<314::aid-jcu6>3.0.co;2-l
pubmed: 9641392
Kempe A, Rösing B, Berg C et al (2007) First-trimester treatment of fetal anemia secondary to parvovirus B19 infection. Ultrasound Obstet Gynecol 29:226–228. https://doi.org/10.1002/uog.3925
doi: 10.1002/uog.3925
pubmed: 17252527
Ornoy A, Ergaz Z (2017) Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res 109:311–323. https://doi.org/10.1002/bdra.23588
doi: 10.1002/bdra.23588
pubmed: 28398685
Fishman SG, Pelaez LM, Baergen RN, Carroll SJ (2011) Parvovirus-mediated fetal cardiomyopathy with atrioventricular nodal disease. Pediatr Cardiol 32:84–86. https://doi.org/10.1007/s00246-010-9803-9
doi: 10.1007/s00246-010-9803-9
pubmed: 20936534
Schenk T, Enders M, Pollak S et al (2009) High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 47:106–110. https://doi.org/10.1128/jcm.01672-08
doi: 10.1128/jcm.01672-08
pubmed: 19005147
Siebers P, Gembruch U, Merz WM et al (2024) Fetal NT-proBNP levels and their course in severe anemia during intrauterine treatment. Arch Gynecol Obstet 309:1341–1351. https://doi.org/10.1007/s00404-023-07006-8
doi: 10.1007/s00404-023-07006-8
pubmed: 36966429
Kosian P, Hellmund A, Geipel A et al (2022) Intrauterine transfusion in 103 fetuses with severe anemia caused by parvovirus infection a multicenter retrospective study. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-022-06712-z
doi: 10.1007/s00404-022-06712-z
pubmed: 35916962
pmcid: 10192140
Haan TD, Akker EVD, Porcelijn L et al (2008) Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. Bjog Int J Obstetrics Gynaecol 115:76–81. https://doi.org/10.1111/j.1471-0528.2007.01555.x
doi: 10.1111/j.1471-0528.2007.01555.x
Zajicek M, Gindes L, Hoffmann C et al (2010) Prenatal diagnosis of obstructive hydrocephalus associated with parvovirus B19 Infection. Obstet Gynecol 116:521–522. https://doi.org/10.1097/aog.0b013e3181e7597e
doi: 10.1097/aog.0b013e3181e7597e
pubmed: 20664440
Enders M, Weidner A, Rosenthal T et al (2008) Improved Diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 197:58–62. https://doi.org/10.1086/524302
doi: 10.1086/524302
pubmed: 18171285
Maple PAC, Hedman L, Dhanilall P et al (2014) Identification of past and recent parvovirus B19 Infection in Immunocompetent individuals by quantitative PCR and enzyme immunoassays: a dual-laboratory study. J Clin Microbiol 52:947–956. https://doi.org/10.1128/jcm.02613-13
doi: 10.1128/jcm.02613-13
pubmed: 24403307
pmcid: 3957764
Yaegashi N (2005) Pathogenesis of nonimmune hydrops fetalis caused by intrauterine B19 infection. Tohoku J Exp Med 190:65. https://doi.org/10.1620/tjem.190.65
doi: 10.1620/tjem.190.65
Abbasi N, Johnson J-A, Ryan G (2017) Fetal anemia. Ultrasound Obstet Gynecol 50:145–153. https://doi.org/10.1002/uog.17555
doi: 10.1002/uog.17555
pubmed: 28782230
Cosmi E, Mari G, Chiaie LD et al (2002) Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol 187:1290–1293. https://doi.org/10.1067/mob.2002.128024
doi: 10.1067/mob.2002.128024
pubmed: 12439522
Martinez-Portilla RJ, Lopez-Felix J, Hawkins-Villareal A et al (2019) Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis. Ultrasound Obstet Gynecol 54:722–731. https://doi.org/10.1002/uog.20273
doi: 10.1002/uog.20273
pubmed: 30932276
Chiaie LD, Buck G, Grab D, Terinde R (2001) Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol 18:232–236. https://doi.org/10.1046/j.0960-7692.2001.00540.x
doi: 10.1046/j.0960-7692.2001.00540.x
Kosian P, Hellmund A, Geipel A et al (2023) Intrauterine transfusion in 103 fetuses with severe anemia caused by parvovirus infection. a multicenter retrospective study. Arch Gynecol Obstet 308:117–125. https://doi.org/10.1007/s00404-022-06712-z
doi: 10.1007/s00404-022-06712-z
pubmed: 35916962
Sánchez-Durán MÁ, Higueras MT, Avilés-García M et al (2020) Perinatal outcomes and central nervous system abnormalities following intrauterine fetal transfusion: 17 years’ experience in a tertiary center. Transfusion 60:2557–2564. https://doi.org/10.1111/trf.16087
doi: 10.1111/trf.16087
pubmed: 32955746
Crawford NEH, Parasuraman R, Howe DT (2020) Intraperitoneal transfusion for severe, early-onset rhesus disease requiring treatment before 20 weeks of gestation: A consecutive case series. Eur J Obstet Gynecol Reprod Biol 244:5–7. https://doi.org/10.1016/j.ejogrb.2019.10.027
doi: 10.1016/j.ejogrb.2019.10.027
pubmed: 31707170
Lindenburg ITM, van Kamp IL, Oepkes D (2014) Intrauterine blood transfusion: current indications and associated risks. Fetal Diagn Ther 36:263–271. https://doi.org/10.1159/000362812
doi: 10.1159/000362812
pubmed: 24903741
Zwiers C, Lindenburg ITM, Klumper FJ et al (2017) Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound obstetric gynecol off j of the Int Soc Ultrasound Obstetric Gynecol 50:180–186. https://doi.org/10.1002/uog.17319
doi: 10.1002/uog.17319
Berezowsky A, Hochberg A, Regev N et al (2023) Intrauterine blood transfusion for parvo B19-induced fetal anemia: neuroimaging findings and long-term neurological outcomes. Fetal Diagn Ther 50:206–214. https://doi.org/10.1159/000530993
doi: 10.1159/000530993
pubmed: 37231949
Lindenburg ITM, van Klink JM, Smits-Wintjens VEHJ et al (2013) Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for fetal anaemia: a review. Prenat Diagn 33:815–822. https://doi.org/10.1002/pd.4152
doi: 10.1002/pd.4152
pubmed: 23658134